Innovative Bispecific Nanobody Targeting CD3 Complex and MS4A1 for Advanced Leukemia Therapy
VHH-P569 is an advanced bispecific, humanized nanobody under development, specifically engineered to target the CD3 Complex (T Cell Receptor Complex) and membrane spanning 4-domains A1 (MS4A1). This molecule leverages a novel single-domain antibody architecture and is currently in the Biological Testing phase. Designed for the treatment of leukemia, VHH-P569 harnesses dual targeting to optimize immune cell engagement and malignant cell recognition. The bifunctional design holds significant promise in addressing unmet clinical challenges associated with leukemia, offering a potentially transformative option for hematological malignancies.
| Candidate | VHH-P569 |
| Target | CD3 Complex (T Cell Receptor Complex) membrane spanning 4-domains A1 (MS4A1) |
| Modality | humanized bispecific VHH |
| Indication | Leukemia |
Licensing Opportunity
VHH-P569 is open for licensing or collaborative development opportunities. We invite partners interested in accelerating its clinical translation and maximizing its therapeutic and commercial impact.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P569 |
Modality
VHH-P569 is a bispecific antibody composed of an anti-human CD3 single-domain antibody and an anti-CD20 fragment antigen-binding region, fused to an IgG1 Fc domain, and produced in Expi293 cells. The nanobody framework provides a compact, robust molecular structure, enabling superior tissue penetration and stability compared to conventional antibodies. Its dual-targeting functionality facilitates enhanced redirection of immune cells to malignant B-cell populations, such as those found in leukemia. The unique structural features of VHH-P569, including its small size and high solubility, are advantageous for improved tumor accessibility and may reduce off-target effects, making it especially attractive for the treatment of leukemia and other B-cell malignancies.
Target
CD3 Complex and MS4A1 are central molecular targets in immunotherapy. CD3 Complex is a key component of the T cell receptor involved in the activation and signaling of T lymphocytes, primarily expressed on T cells. MS4A1, also known as CD20, is a prominent B-cell marker that plays an essential role in B-cell development and is predominantly found on the surface of mature B lymphocytes. Both CD3 Complex and MS4A1 are validated targets in hematological malignancies including leukemia, as malignant cells frequently express MS4A1 and harnessing T cells via CD3 Complex can enable selective cytotoxicity. By focusing on both CD3 Complex and MS4A1, VHH-P569 offers a strategic advantage to bridge immune effectors and target cell lysis in leukemia therapy, supporting its differentiation in a competitive field.
Mechanism of Action
VHH-P569 acts as a bispecific T-cell engager by simultaneously binding to CD3 Complex on T lymphocytes and MS4A1 on malignant B cells. The engagement of CD3 Complex leads to T cell activation, while the simultaneous recognition of MS4A1 facilitates targeted cytotoxicity against leukemia cells. This mechanism modulates signal transduction pathways to redirect immune effector functions selectively toward malignant cells. The nanobody platform underlying VHH-P569 enables modular design, supporting future development into therapeutic formats such as dual-targeted biologics and potentially antibody-drug conjugates. This functional versatility expands its therapeutic horizon and creates value for further clinical applications beyond leukemia.
Leukemia
Leukemia encompasses a heterogeneous group of hematological cancers arising from the uncontrolled proliferation of white blood cells, often of B-cell or T-cell origin. Globally, leukemia represents a significant health burden, with rising incidence observed across both adult and pediatric populations. Standard-of-care therapies include chemotherapy, radiotherapy, immunotherapies, and hematopoietic stem cell transplantation. While advancements have improved outcomes for some patients, current therapies are frequently limited by relapse rates, toxicity, and resistance. Targeted biologics have emerged as promising additions but still leave substantial unmet needs, particularly in relapsed/refractory settings and cases with minimal residual disease. VHH-P569, through dual targeting of CD3 Complex and MS4A1, proposes a new modality for highly selective, immune-mediated cytotoxicity against leukemia cells, potentially overcoming immune evasion and resistance mechanisms, and thus holds substantial therapeutic potential in this challenging landscape.